Decision catalogueModality pressure-test
In oligonucleotide packages, delivery is often the product claim
Decision problem
Is the check buying a product path in the intended tissue, or unresolved delivery science?
Thesis
If biodistribution and redosing assumptions rest on weak class analogues, the financing narrative is a delivery project wearing an asset label.
Nucleotide programs are easy to mis-frame as chemistry platforms. For seed and Series A decisions, the scarce question is whether delivery and durability evidence matches the tissue and dosing story in the deck.
The review pressure-tests three claims early: exposure in the intended compartment, durability consistent with the redosing narrative, and a safety monitoring plan sized to known oligonucleotide failure modes. Extrahepatic targeting language without asset-level data is a common overclaim.
Platform-versus-asset framing decides the memo shape. A platform can be interesting; an asset-sized check still needs asset-level evidence.
Claim map
Must-be-true cuts a Decision Sprint memo would force
- Delivery and biodistribution are evidenced for the intended tissue
- Durability and redosing assumptions match the financing narrative
- Safety / off-target risk is bounded enough for the proposed study design
Decision triggers
Outputs from the claim test that should change the conversation
- Platform story carrying an asset decision without asset-level exposure data
- Delivery claim resting on analogue classes with weak comparability
- Safety monitoring thinner than the modality’s known failure modes
Sources
Related in the catalogue
- Prior work · Nucleotide therapeutics
Anonymized account of decision pressure in this modality class.
- Method · graph-backed claim testing
How claims are decomposed, tested against the evidence graph, and turned into decision outputs.
- Platform story, asset check: separate them before you commit
Is this raise underwriting a product path or an unresolved platform science project?
- Claim maps beat generic diligence checklists for seed decisions
How should a lean team pressure-test science under a 5–20 day deal deadline?
Facing this cut on a live $1–10M package?
Scope a Decision Sprint for one opportunity under your deal deadline—claim map, risk register, management questions, and partner briefing.